TY  - JOUR
SP  - 19
TI  - Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3
A1  -  Kemény Lajos
A1  -  Berggren Lovisa
A1  -  Dossenbach Martin
A1  -  Dutronc Yves
A1  -  Paul Carl
SN  - 0954-6634
EP  - 26
ID  - publicatio20075
JF  - JOURNAL OF DERMATOLOGICAL TREATMENT
AV  - public
N2  - PURPOSE: To evaluate short- and long-term efficacy and safety of ixekizumab in patients according to psoriasis severity. MATERIALS AND METHODS: Data were integrated from clinical trials (UNCOVER-2, UNCOVER-3). Patients received placebo, 80-mg ixekizumab every 2 weeks (IXEQ2W), every 4 weeks (IXEQ4W), or 50-mg etanercept (ETN) biweekly for 12 weeks, then open-label IXEQ4W (UNCOVER-3). Psoriasis severity was categorized by baseline Psoriasis Area and Severity Index (PASI <20 and >/=20). Efficacy was evaluated by percentage reaching PASI 75, 90, 100, and absolute PASI </=5, </=2, and </=1. RESULTS: Significantly more patients with PASI >/=20 (vs. PASI <20) were male and had higher body weight. After 12 weeks, both severity groups had significantly more IXEQ2W- than ETN-treated patients reach PASI 75, 90, 100, and absolute PASI </=5, </=2, </=1. Fewer PASI >/=20 vs. PASI <20 patients across treatments reached PASI </=5, </=2, and </=1 at Week 12. Efficacy was maintained during 156 weeks of ixekizumab treatment with no differences between groups. The IXEQ2W safety profile was similar between groups except for injection-site reactions (significantly higher in PASI <20). CONCLUSIONS: Ixekizumab demonstrated a high level of efficacy and had a consistent safety profile in patients with different baseline psoriasis severity levels.
IS  - 1
Y1  - 2019///
UR  - http://doi.org/10.1080/09546634.2018.1473551
VL  - 30
ER  -